Skip to main content
Fig. 1 | Arthritis Research & Therapy

Fig. 1

From: Effectiveness of two different doses of rituximab for the treatment of rheumatoid arthritis in an international cohort: data from the CERERRA collaboration

Fig. 1

a Disease activity based on Disease Activity Score in 28 joints (DAS28)-erythrocyte sedimentation rate (ESR) at baseline, 3 and 6 months in the two treatment groups (rituximab (RTX) 500 mg × 2 and RTX 1000 mg × 2). No significant differences were observed: remission, DAS28 <2.6; low disease activity, 2.6≤ DAS28 ≤3.2; moderate disease activity, 3.2< DAS28 ≤5.1; high disease activity, DAS28 >5.1. b. Good, moderate or no European League Against Rheumatism (EULAR) response at 6 months for the two treatment groups (RTX 500 mg × 2 and RTX 1000 mg × 2). No significant differences were observed

Back to article page

Arthritis Research & Therapy

ISSN: 1478-6362

Contact us